










Winter 2019/2020

Northern Lincolnshire Area Prescribing committee Newsletter

Traffic Light Status Information

Status	Description
 GREEN	Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMBER	Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.
 RED	Red-Hospital initiation and continuation only
 AMB SCP	AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised
 BLUE	To be supplied from the appropriate commissioned provider.
 GREEN 2	GREEN 2- to be prescribed by primary care only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)



Winter 2019/2020

1. Formulary Amendments and Additions

Name of Drug	RAG Rated	Information
Ceftriaxone	Dual status	Red and hospital only for all indication except for pelvic inflammatory disease whereby it is green http://www.apcni/formulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=5&SubSectionRef=05.01.02.01&SubSectionID=A100&drugmatch=1757#1757
<u>Ranolazine</u>	Amber	All prescribing to be carried out as per the prescribing arrangements set out in the following document http://www.apcni/formulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=2&SubSectionRef=02.06.03&SubSectionID=A100&drugmatch=3209#3209
Penicillamine	AMBER SCP	Approved at APC with supporting shared care protocol in place http://www.apcni/formulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=10&SubSectionRef=10.01.03&SubSectionID=C100&drugmatch=2615#2615
<u>Freestyle Libre (glucose Monitoring System)</u>	AMBER	All prescribing to be carried out as per the prescribing arrangements set out in the following document https://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2019/08/Prescribing-Arrangements-for-Flash-Glucose-Monitoring-Final-2.pdf
Sacubutril Valsartan – entresto	Amber	Agreed As amber with a supporting prescribing guideline. http://www.apcni/formulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=2&SubSectionRef=02.15&SubSectionID=A100
Diazoxide	Red	Unlicensed formulation approved as hospital only
<u>Metvix</u>	RED	Approved as RED for specialist/dermatologist to prescribe only



Winter 2019/2020

2) NICE Technical Appraisals

NICE TA	Indication	RAG rating
NICE TA588	Nusinersen for treating spinal muscular atrophy – Not Applicable – NLaG are not commissioned to deliver services associated with spinal muscular atrophy.	RED
NICE TA589	Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual activity	RED
NICE TA590	Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	RED
NICE TA591	Letermovir for preventing cytomegalovirus disease after a stem cell transplant	RED
NICE TA592	Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma	RED
NICE TA584	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	RED
NICE TA595	Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer	RED
NICE TA596	Risankizumab for treating moderate to severe plaque psoriasis	RED
NICE TA597	Dapagliflozin with insulin for treating type 1 diabetes	GREEN
NICE TA598	Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	RED
NICE TA599	Sodium zirconium cyclosilicate for treating hyperkalaemia	RED
NICE TA600	Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer.	RED
NICE TA 565	Benralizumab for treating severe eosinophilic asthma (updated)	RED
NICE TA604	Idelalisib for treating refractory follicular lymphoma	RED
NICE TA605	Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea	RED
NICE TA606	Lanadelumab for preventing recurrent attacks of hereditary angioedema	RED
NICE TA607	Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	GREEN



Winter 2019/2020

3) Items Approved at APC

Approved prescribing Guidelines

The Following Guidelines were approved:

- Sacubutril Valsartan prescribing guideline
- Ranolazine prescribing guideline

Rheumatology Shared Care Guidelines

The following shared care guidelines were approved:

- Prescribing Framework for Penicillamine

In practical terms the shared care guidelines will be initially published on the Northern Lincolnshire and Goole trust intranet. Ensuring correct blood test forms are in place and ready to use prior to going live.

4) MHRA Alerts

The latest MHRA Alerts are published here: www.gov.uk/government/publications/drug-safety-update-monthly-newsletter

5) Net Formulary update

We are continuing to update our Formulary available at: www.apcnlgformulary.nhs.uk

Net Formulary holds information about drugs and their formulary status. It also includes traffic light status of medications so that prescriber responsibilities are clear. Pathways, NICE and APC policies will be linked to this as well as APC minutes and policies. This is an active document which is being continually updated. Please feel free to provide feedback or comments to the Area Prescribing Professional secretary Aliya Turk at aliya.turk@nhs.net The net Formulary app is now being rolled out, information on how to install the app can be found on the formulary website under net Formulary APP.